methyl 5-hydroxy-8-methyl-2-(4-(trifluoromethyl) phenoxy)-1,7-naphthyridine-6-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: methyl 5-hydroxy-8-methyl-2-(4-(trifluoromethyl) phenoxy)-1,7-naphthyridine-6-carboxylate
• 英文别名: Methyl 5-hydroxy-8-methyl-2-[4-(trifluoromethyl)phenoxy]-1,7-naphthyridine-6-carboxylate；methyl 5-hydroxy-8-methyl-2-[4-(trifluoromethyl)phenoxy]-1,7-naphthyridine-6-carboxylate
• 化学式: C₁₈H₁₃F₃N₂O₄
• 分子量: 378.307
• InChiKey: WCGOLMIGCJXFHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  81.5
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 5-hydroxy-8-methyl-2-(4-(trifluoromethyl) phenoxy)-1,7-naphthyridine-6-carboxylate 、 聚甘氨酸 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 20.0h， 以22.1%的产率得到2-(5-hydroxy-8-methyl-2-(4-(trifluoromethyl)phenoxy)-1,7-naphthyridine-6-formamido)acetic acid
  参考文献：
  名称：

  COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF

  摘要：

  公开号：

  EP3275881B1
• 作为产物：
  描述：

  2,6-二氯吡啶-3-羧酸甲酯 在 三乙烯二胺 、 N-溴代丁二酰亚胺(NBS) 、 1,2-双(二苯基膦)乙烷氯化镍 、 偶氮二异丁腈 、 sodium methylate 、 potassium carbonate 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 四氯化碳 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 methyl 5-hydroxy-8-methyl-2-(4-(trifluoromethyl) phenoxy)-1,7-naphthyridine-6-carboxylate
  参考文献：
  名称：

  COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF

  摘要：

  公开号：

  EP3275881B1

文献信息

• Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof
  申请人：SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD.

  公开号：US10100051B2

  公开（公告）日：2018-10-16

  A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein R2 and R3 are each independently H; R1 is H or C1-C3 alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO.

  本发明提供了一种被芳基氧基或杂芳基氧基取代的 5-羟基-1,7-萘啶的化合物、其制备方法及其药物用途。特别是，该化合物具有下式（I），其中 R2 和 R3 各自独立地为 H；R1 为 H 或 C1-C3 烷基；Ar 为选自萘环、吡啶环、噻吩环、呋喃环和取代苯环的芳环或杂芳环。提供了本化合物的药学上可接受的盐，以及本化合物或其药学上可接受的盐在制备抑制 HIF 脯氨酰羟化酶的药物或促进内源性 EPO 生成的药物中的用途。
• COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
  申请人：SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD.

  公开号：US20180118739A1

  公开（公告）日：2018-05-03

  A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein R 2 and R 3 are each independently H; R 1 is H or C 1 -C 3 alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO.
• COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
  申请人：Shenyang Sunshine Pharmaceutical Co., Ltd.

  公开号：EP3275881B1

  公开（公告）日：2021-08-04